Tradestie Institutional Equity Comparison Engine

IMVT vs XNCR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IMVT Overall Edge

IMVT Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunovant, Inc. Common Stock (IMVT) driven by superior Growth & Margin, Options & Structure while XNCR counters with relative strength in Valuation, Momentum & Technical. Fundamentally, IMVT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus XNCR at 68.0x Forward P/E and -72.7% operating margin (+454.9% YoY). In options structure, IMVT sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against XNCR sits in BREAKOUT (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XNCR
IMVT N/M vs XNCR 68.0x Fwd P/E
Growth & Margin Winner IMVT
Op Margin 0.0% vs -72.7% ยท YoY +0.0% vs +454.9%
Momentum & Technical Winner XNCR
1Y +46.0% vs +154.5% ยท 52W Pos 49% vs 84%
Options & Structure Winner IMVT
CONSOLIDATION (6th %ile IV) vs BREAKOUT (10th %ile IV)
IMVT NASDAQ
Immunovant, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$33.30
-2.56% 1D
Market Cap $7.3B
1M Return +24.6%
1Y Return +45.95%
Forward P/E N/M
Unified AI Score
39.6 / 100 SELL
Tech 15.0 Fund 36.0 Flow 68.0 Mom 50.0
XNCR NASDAQ
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
1M Return +55.84%
1Y Return +154.54%
Forward P/E 68.0x
Unified AI Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMVT +45.95% XNCR +154.54% Spread: +108.59 pp (XNCR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IMVT TTM Op. Margin: 0.0% XNCR TTM Op. Margin: -72.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMVT vs XNCR. Trailing 12-month operating profitability (IMVT 0.0% vs XNCR -72.7%) and valuation multiples (IMVT N/M vs XNCR 68.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMVT (5) vs XNCR (5)
Institutional Metric IMVT XNCR Criterion Row Winner
Market Capitalization Scale $7.3B $2.9B Larger Scale IMVT
Trailing P/E Ratio Valuation N/M 68.0x Lower Multiple XNCR
Forward P/E Ratio Valuation N/M 68.0x Lower Multiple XNCR
Revenue Growth (YoY) Growth +0.0% +454.9% Higher Growth XNCR
Operating Margin (TTM) Profitability 0.0% -72.7% Higher Margin IMVT
Net Profit Margin Profitability 0.0% -58.8% Higher Margin IMVT
Return on Equity (ROE) Capital Efficiency -86.5% -19.9% Higher ROE XNCR
52-Week Range Position Momentum 49% ($22โ€“$45) 84% ($10โ€“$41) Stronger Trend XNCR
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 72% Vol 1.21ฮฒ ยท 87% Vol Lower Realized Risk IMVT
Unified Institutional Score Composite Signal 39.6 / 100 (SELL) 29.6 / 100 (SELL) Higher Composite IMVT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMVT vs XNCR Buy Guide
IMVT CONSOLIDATION
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live IMVT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XNCR BREAKOUT
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live XNCR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMVT nor XNCR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.